Plain-English translation of NCT07234591 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new medication called a to see if it can help people with moderate to severe plaque psoriasis. The study will last 12 weeks and will compare this medication to a placebo (a dummy pill with no active ingredient) to measure how well the treatment works and whether it is safe. About 140 people will participate, and each person will be randomly assigned to receive one of three different doses of the medication or the placebo.
Plaque psoriasis is a chronic skin condition that can significantly impact quality of life, and current treatment options don't work well enough for everyone. This trial aims to determine whether this new medication could be a safe and effective option for people with moderate to severe psoriasis who need better treatment.
You likely qualify if…
You likely don't qualify if…
You would take the medication or placebo by mouth for 12 weeks as part of a randomized group. You won't know whether you're receiving the actual medication or the placebo — this helps researchers get accurate results. During the study, you'll have regular visits to the clinic where the research team will monitor your skin, check how well the treatment is working, and watch for any side effects.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China
Sponsor
Usynova Pharmaceuticals Ltd.
Enrollment target
~140 participants
Started
October 2025
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yang Zhang
Usynova Pharmaceuticals Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.